Literature DB >> 28320619

Questions in the comparative effectiveness of dabigatran and warfarin in atrial fibrillation.

Alvaro Alonso1, Pamela L Lutsey2, Lin Y Chen3, Richard F MacLehose2, Lindsay G S Bengtson4.   

Abstract

Entities:  

Keywords:  Anticoagulation; Atrial fibrillation; Comparative effectiveness

Mesh：

Substances：

Year:  2017        PMID： 28320619      PMCID： PMC5550293          DOI： 10.1016/j.jjcc.2017.02.003

Source DB:  PubMed          Journal:  J Cardiol        ISSN： 0914-5087            Impact factor:   3.159


× No keyword cloud information.
  5 in total

1.  Effect and risk of novel oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.

Authors:  Tomoyuki Kawada
Journal:  J Cardiol       Date:  2017-02-13       Impact factor: 3.159

2.  Association of Selective Serotonin Reuptake Inhibitors With the Risk for Spontaneous Intracranial Hemorrhage.

Authors:  Christel Renoux; Sarah Vahey; Sophie Dell'Aniello; Jean-François Boivin
Journal:  JAMA Neurol       Date:  2017-02-01       Impact factor: 18.302

3.  Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation.

Authors:  Yi-Hsin Chan; Kun-Chi Yen; Lai-Chu See; Shang-Hung Chang; Lung-Sheng Wu; Hsin-Fu Lee; Hui-Tzu Tu; Yung-Hsin Yeh; Chi-Tai Kuo
Journal:  Stroke       Date:  2016-01-05       Impact factor: 7.914

4.  High-dimensional propensity score adjustment in studies of treatment effects using health care claims data.

Authors:  Sebastian Schneeweiss; Jeremy A Rassen; Robert J Glynn; Jerry Avorn; Helen Mogun; M Alan Brookhart
Journal:  Epidemiology       Date:  2009-07       Impact factor: 4.822

5.  Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation.

Authors:  Lindsay G S Bengtson; Pamela L Lutsey; Lin Y Chen; Richard F MacLehose; Alvaro Alonso
Journal:  J Cardiol       Date:  2016-11-23       Impact factor: 3.159
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.